Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Researchers propose new treatment to prevent mucositis in cancer patients

Experimental work pointing to a therapy for alleviating mucositis -- a common, severe side effect of chemotherapy and irradiation of cancer patients or patients prepared for bone marrow transplantation - has been achieved by an international team of researchers from the US and Israel headed by scientists at the Hebrew University of Jerusalem.

20 Feb 2014

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Adding bevacizumab (Avastin) to standard chemotherapy and radiation treatment does not improve survival for patients newly diagnosed with the often deadly brain cancer glioblastoma, researchers report in the Feb. 20 issue of the New England Journal of Medicine.

20 Feb 2014

Researchers receive $3M grant to develop targeted cancer drugs and repair damaged arteries

The National Institutes of Health has awarded grants totaling $3 million for two nanoparticle research projects in which Penn State bioengineer Jian Yang is co-principal investigator.

19 Feb 2014

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

CytoDyn Inc., a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company has submitted a Phase 2b clinical trial protocol, for its lead product candidate, PRO 140, to the U.S. Food and Drug Administration for treatment substitution in patients with Human Immunodeficiency Virus (HIV).

19 Feb 2014

New research may provide insight on how dengue virus gains entry into cells

Dengue fever, an infectious tropical disease caused by a mosquito-borne virus, afflicts millions of people each year, causing fever, headache, muscle and joint pains and a characteristic skin rash. In some people the disease progresses to a severe, often fatal, form known as dengue hemorrhagic fever.

18 Feb 2014

Novimmune closes Series B financing for CHF 60 million

Novimmune SA announced that it has closed a Series B financing for CHF 60 million ($66 million). London-based Rosetta Capital Limited led the round with participation of new private investors as well as existing investors.

18 Feb 2014

Polyplus-transfection grants research license to NIH for PEI-mediated transfection applications

Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.

17 Feb 2014

Novartis acquires CoStim Pharmaceuticals

MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

17 Feb 2014

Scientists discover novel antibody-based therapy that targets progression of kidney fibrosis

Scientists from the University of Sheffield have developed a novel antibody-based therapy which targets the progression of life threating kidney fibrosis.

16 Feb 2014

Exposure to common infections linked to memory and brain function

Exposure to common infections is linked to memory and brain function - even if the infections never made you ill, according to research presented at the American Stroke Association's International Stroke Conference 2014.

13 Feb 2014

Fluidigm acquires DVS Sciences

Fluidigm Corp. today announced it has completed its acquisition of DVS Sciences, Inc. With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms to create a comprehensive portfolio of advanced technologies serving the rapidly growing single-cell genomics and proteomics markets.

13 Feb 2014

Agenus closes previously announced acquisition of 4-Antibody

Agenus Inc., a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.

13 Feb 2014

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

13 Feb 2014

Researchers identify effective target for human autoimmune disease

Researchers at King's College London have identified a new gene (PIM1), which could be an effective target for innovative treatments and therapies for the human autoimmune disease, psoriasis.

13 Feb 2014

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the company was awarded U.S. Patent No. 8,647,626, entitled "Compositions Comprising TNF-specific Antibodies for Oral Delivery."

12 Feb 2014

Scientists find neutralizing antibodies that protects humanized mice from HIV transmission

NIH-funded scientists have shown that boosting the production of certain broadly neutralizing antibodies can protect humanized mice from both intravenous and vaginal infection with HIV. Humanized mice have immune systems genetically modified to resemble those of humans, making it possible for them to become HIV-infected.

12 Feb 2014

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Discovering key elements of immune system T cell biology and applying that knowledge to create a new way to treat cancer has earned Jim Allison, Ph.D., the 2014 Szent-Györgyi Prize for Progress in Cancer Research from the National Foundation for Cancer Research.

10 Feb 2014

Finding could lead to first effective vaccine against respiratory syncytial virus

Vanderbilt University scientists have contributed to a major finding, reported today in the journal Nature, which could lead to the first effective vaccine against respiratory syncytial virus (RSV), a significant cause of infant mortality.

9 Feb 2014

TSRI scientists discover unusual protein that probably helps some bacteria evade immune response

A team led by scientists at The Scripps Research Institute (TSRI) has discovered an unusual bacterial protein that attaches to virtually any antibody and prevents it from binding to its target. Protein M, as it is called, probably helps some bacteria evade the immune response and establish long-term infections.

7 Feb 2014

Researchers design microfluidic platform to see how cancer cells invade specific organs

Nearly 70 percent of patients with advanced breast cancer experience skeletal metastasis, in which cancer cells migrate from a primary tumor into bone - a painful development that can cause fractures and spinal compression.

7 Feb 2014

Antibody News and Research

Further Reading

Researchers propose new treatment to prevent mucositis in cancer patients

Bevacizumab offers no benefit for patients newly diagnosed with glioblastoma

Researchers receive $3M grant to develop targeted cancer drugs and repair damaged arteries

CytoDyn submits PRO 140 Phase 2b trial protocol to FDA for treatment substitution in HIV patients

New research may provide insight on how dengue virus gains entry into cells

Novimmune closes Series B financing for CHF 60 million

Polyplus-transfection grants research license to NIH for PEI-mediated transfection applications

Novartis acquires CoStim Pharmaceuticals

Scientists discover novel antibody-based therapy that targets progression of kidney fibrosis

Exposure to common infections linked to memory and brain function

Fluidigm acquires DVS Sciences

Agenus closes previously announced acquisition of 4-Antibody

Alvogen launches Inflectra into Central and Eastern Europe

Researchers identify effective target for human autoimmune disease

Avaxia Biologics receives patent for oral anti-TNF antibodies for treatment of IBD

Scientists find neutralizing antibodies that protects humanized mice from HIV transmission

Immunology professor receives 2014 Szent-Györgyi Prize for progress in cancer research from NFCR

Finding could lead to first effective vaccine against respiratory syncytial virus

TSRI scientists discover unusual protein that probably helps some bacteria evade immune response

Researchers design microfluidic platform to see how cancer cells invade specific organs

Immunology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News